2-(Methoxycarbonylamino)-3-methylsulfanylpropanoic acid | 64356-96-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(Methoxycarbonylamino)-3-methylsulfanylpropanoic acid
• CAS: 64356-96-3
• 化学式: C₆H₁₁NO₄S
• 分子量: 193.224
• InChiKey: OBNBXGQDMXYQDD-UHFFFAOYSA-N

物化性质

• 沸点：
  375.9±37.0 °C(Predicted)
• 密度：
  1.298±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  dimethyl aziridine-1,2-dicarboxylate 在 氢氧化钾 、 三氟化硼乙醚 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 2-(Methoxycarbonylamino)-3-methylsulfanylpropanoic acid
  参考文献：
  名称：

  N-取代的氮丙啶-2-羧酸酯的合成

  摘要：

  描述了通过使2-氯-N-碳烷氧基甘氨酸甲酯1与重氮甲烷反应来合成N-甲氧基羰基-和N-苄氧基羰基氮丙啶-2-羧酸2的甲酯的方法。氮丙啶易于转化为O-甲基丝氨酸5和S-甲基半胱氨酸6的衍生物。

  DOI：

  10.1016/0040-4020(77)80039-2

文献信息

• O-LINKED GLYCOSYLATION OF PEPTIDES
  申请人：DeFrees Shawn

  公开号：US20080242846A1

  公开（公告）日：2008-10-02

  The present invention provides polypeptides that include an O-linked glycosylation site that is not present in the wild-type peptide. The polypeptides of the invention include glycoconjugates in which a species such as a water-soluble polymer, a therapeutic agent of a biomolecule is covalently linked through an intact O-linked glycosyl residue to the polypeptide. Also provided are methods of making the peptides of the invention and methods, pharmaceutical compositions containing the peptides and methods of treating, ameliorating or preventing diseased in mammals by administering an amount of a peptide of the invention sufficient to achieve the desired response.

  本发明提供了包含一个O-连接糖基化位点的多肽，该位点在野生型多肽中不存在。本发明的多肽包括糖共轭物，其中一种物质，如水溶性聚合物、生物分子的治疗剂量通过完整的O-连接糖基残基与多肽共价连接。本发明还提供了制备本发明多肽的方法、含有该多肽的制药组合物以及通过给予本发明多肽的量来治疗、改善或预防哺乳动物疾病的方法。
• PURIFICATION OF PEPTIDE CONJUGATES BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY
  申请人：DeFrees Shawn

  公开号：US20120016105A1

  公开（公告）日：2012-01-19

  The present invention provides polypeptides that include an O-linked glycosylation site that is not present in the wild-type peptide. The polypeptides of the invention include glycoconjugates in which a species such as a water-soluble polymer, a therapeutic agent of a biomolecule is covalently linked through an intact O-linked glycosyl residue to the polypeptide. Also provided are methods of making a glycoconjugate, methods of isolating a glycoconjugate from a reaction mixture, pharmaceutical compositions containing a glycoconjugate, and methods of treating, ameliorating or preventing diseased in mammals by administering an amount of a glycoconjugate sufficient to achieve the desired response.

  本发明提供了包括一个O-连接糖基化位点的多肽，该位点不存在于野生型多肽中。本发明的多肽包括糖基共轭物，其中一种物种，如水溶性聚合物、生物分子的治疗剂通过完整的O-连接糖基残基与多肽共价连接。还提供了制备糖基共轭物的方法、从反应混合物中分离糖基共轭物的方法、含有糖基共轭物的药物组合物以及通过给予足够量的糖基共轭物来治疗、改善或预防哺乳动物疾病的方法，以达到所需的反应。
• O-linked glycosylation of peptides
  申请人：DeFrees Shawn

  公开号：US20090169509A1

  公开（公告）日：2009-07-02

  The present invention provides polypeptides that include an O-linked glycosylation site that is not present in the wild-type peptide. The polypeptides of the invention include glycoconjugates in which a species such as a water-soluble polymer, a therapeutic agent of a biomolecule is covalently linked through an intact O-linked glycosyl residue to the polypeptide. Also provided are methods of making the peptides of the invention and methods, pharmaceutical compositions containing the peptides and methods of treating, ameliorating or preventing diseased in mammals by administering an amount of a peptide of the invention sufficient to achieve the desired response.

  本发明提供了一种包括不在野生型肽中存在的O-连接糖基化位点的多肽。本发明的多肽包括糖共轭物，其中像水溶性聚合物、生物分子的治疗剂等物种通过完整的O-连接糖基残基与多肽共价结合。本发明还提供了制备该多肽的方法、含有该多肽的制药组合物以及通过给予本发明的多肽的量足以达到所需反应的方法，用于治疗、改善或预防哺乳动物的疾病。
• BERNSTEIN Z.; BEN-ISHAI D., TETRAHEDRON <TETR-AB>, 1977, 33, NO 8, 881-883
  作者：BERNSTEIN Z.、 BEN-ISHAI D.

  DOI：——

  日期：——
• Glycopegylated granulocyte colony stimulating factor
  申请人：DeFrees Shawn

  公开号：US20070014759A1

  公开（公告）日：2007-01-18

  The present invention provides conjugates between Granulocyte Colony Stimulating Factor and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto either an amino acid or glycosyl residue on the peptide. Also provided are pharmaceutical formulations including the conjugates. Methods for preparing the conjugates are also within the scope of the invention.